PMID- 17273811
OWN - NLM
STAT- MEDLINE
DCOM- 20071003
LR  - 20181113
IS  - 0770-3198 (Print)
IS  - 0770-3198 (Linking)
VI  - 26
IP  - 9
DP  - 2007 Sep
TI  - No effects of adalimumab therapy on the activation of NF-kappaB in lymphocytes 
      from patients with severe rheumatoid arthritis.
PG  - 1499-504
AB  - The aim of this study was to determine the activation level of the 
      pro-inflammatory transcription factor nuclear factor kappaB (NF-kappaB) in 
      lymphocytes of patients with rheumatoid arthritis (RA) before and during an 
      anti-tumor necrosis factor alpha (TNFalpha) therapy (adalimumab). In addition, we 
      analyzed the inflammatory markers, interleukin 6 (IL-6), and C-reactive protein 
      (CRP) and investigated the expression of rheumatoid factor (RF) and anti-cyclic 
      citrullinated peptide (anti-CCP) autoantibodies in patients' sera. Twenty RA 
      patients and 20 control subjects were investigated. RA patients' characteristics 
      were evaluated by radiography and disease activity score 28 (DAS 28). Twelve 
      weeks of adalimumab therapy was effective in the treatment of RA patients, as 
      shown by a significant improvement of the DAS 28. The inflammatory markers IL-6 
      and CRP were significantly different in sera of RA patients compared to the 
      control group before the onset of therapy and exhibited a tendency to return to 
      normal levels during the first 12 weeks of therapy. We measured a comparable 
      activation level of NF-kappaB in lymphocytes of control subjects and of RA 
      patients before starting adalimumab therapy. During the following 12 weeks, no 
      significant changes in the activation levels of both NF-kappaB subunits were 
      detected. Serum concentration of RF was significantly lower after 12 weeks, 
      whereas anti-CCP antibody level remained constant.
FAU - Semmler, Marco
AU  - Semmler M
AD  - Department of Internal Medicine and Center of Rheumatology, Rostock Clinic South, 
      Sudring 81, 18059, Rostock, Germany.
FAU - Seeck, Ulrike
AU  - Seeck U
FAU - Neustadt, Beate
AU  - Neustadt B
FAU - Schulz, Martin
AU  - Schulz M
FAU - Dotzlaw, Helmut
AU  - Dotzlaw H
FAU - Neeck, Gunther
AU  - Neeck G
FAU - Eggert, Martin
AU  - Eggert M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20070202
PL  - Germany
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Interleukin-6)
RN  - 0 (NF-kappa B)
RN  - 0 (Peptides, Cyclic)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (cyclic citrullinated peptide)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - 9009-79-4 (Rheumatoid Factor)
RN  - FYS6T7F842 (Adalimumab)
SB  - IM
MH  - Adalimumab
MH  - Adult
MH  - Antibodies, Monoclonal/blood/*pharmacology
MH  - Antibodies, Monoclonal, Humanized
MH  - Arthritis, Rheumatoid/blood/*drug therapy
MH  - C-Reactive Protein/drug effects
MH  - Female
MH  - Humans
MH  - Interleukin-6/blood
MH  - Lymphocytes/*drug effects
MH  - Male
MH  - Middle Aged
MH  - NF-kappa B/*drug effects/physiology
MH  - Peptides, Cyclic/immunology
MH  - Rheumatoid Factor/drug effects
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors/blood
EDAT- 2007/02/03 09:00
MHDA- 2007/10/04 09:00
CRDT- 2007/02/03 09:00
PHST- 2006/12/15 00:00 [received]
PHST- 2007/01/06 00:00 [accepted]
PHST- 2007/01/04 00:00 [revised]
PHST- 2007/02/03 09:00 [pubmed]
PHST- 2007/10/04 09:00 [medline]
PHST- 2007/02/03 09:00 [entrez]
AID - 10.1007/s10067-007-0540-2 [doi]
PST - ppublish
SO  - Clin Rheumatol. 2007 Sep;26(9):1499-504. doi: 10.1007/s10067-007-0540-2. Epub 
      2007 Feb 2.